Latest
AD HOC NEWS Market update
Current financial headlines
Sharemaestro Newsreel
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
- Showing
- 1–36
- Headlines
- 44
- Sources here
- 13
- Companies here
- 6
Current section
Germany Drug Manufacturers - Specialty & Generic news
Chronological news
Latest headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Michael Burry Sends Fresh AI Warning on Nebius, Micron and Oracle
This article first appeared on GuruFocus. Michael Burry (Trades, Portfolio) has increased bearish positions tied to artificial intelligence and semiconductor stocks, while adding to selected long holdings, according to a Wednesday Substack post. Warning! GuruFocus has detected 3 Warning Signs with MU. Is MU …
ZOE
mentioned
Sharemaestro market context
Price below Trend Line
52 weeks -49.9%
Viatris (VTRS) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, August 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS CEO - Scott SmithInterim CFO - Paul CampbellChief R&D Officer - Philippe MartinChief Commercial Officer - Corinne Le GoffHead of Capital Markets - Bill Szablewski TAKEAWAYS Revenue -- …
VIA
main company
Sharemaestro market context
Trend signal active
52 weeks +66.1%
Zoetis (ZTS) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Steve FrankChief Executive Officer - Kristin PeckChief Financial Officer - Wetteny Joseph TAKEAWAYS Revenue -- $2.5 billion, representing a flat result on …
ZOE
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.9%
Burry adds to AI shorts, says ‘Nebius is what the top of a boom looks like’
Astrid Stawiarz Michael Burry disclosed updated stock positions on Wednesday, adding to his short bets on Nebius (NBIS [https://seekingalpha.com/symbol/NBIS]), Micron (MU [https://seekingalpha.com/symbol/MU]), Oracle (ORCL [https://seekingalpha.com/symbol/ORCL]), and the iShares Semiconductor ETF (SOXX [https://seekingalpha.com/symbol/SOXX]), while increasing his long positions in Mercado Libre (MELI [https://seekingalpha.com/symbol/MELI]) and Zoetis …
ZOE
mentioned
Sharemaestro market context
Price below Trend Line
52 weeks -49.9%
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
Amneal Pharmaceuticals AMRX enters the second half of 2026 with higher guidance and a broader product pipeline. The company is expanding complex generics, biosimilars and specialty medicines while adjusted earnings and EBITDA improve. The trade-off is clear. Rytary has lost exclusivity, generic pricing remains …
VIA
mentioned
Sharemaestro market context
Trend signal active
52 weeks +66.1%
Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Disease
Funding brings total capital raised to $62 million as the Company expands pharmaceutical co-development partnerships and accelerates the Hybrid Drug category NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Remepy, the pioneer of Hybrid Drugs, today announced the closing of a $36 million Series A …
MRK
main company
Sharemaestro market context
Trend signal active
52 weeks +30.8%
Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes
LONDON, Aug. 11, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that its wholly owned subsidiary, Haleon US Capital LLC (the "Offeror") is offering to buy back any and all of its outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes …
H6D0
main company
Sharemaestro market context
Price above Trend Line
52 weeks +6.2%
VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook
VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook Medication company Viatris (NASDAQ:VTRS) announced better-than-expected revenue in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year's revenue to be around $14.75 …
VIA
main company
Sharemaestro market context
Trend signal active
52 weeks +66.1%
Haleon and Singapore's Agency for Science, Technology and Research (A*STAR) Launch New Clinical Study on Women's Metabolic Health in Asia
A new clinical study on the multivitamin and mineral supplement Centrum is designed to generate evidence on metabolic health in midlife Asian women - a group often underrepresented in global nutrition research. The study will contribute to a better understanding of preventive healthcare and …
H6D0
main company
Sharemaestro market context
Price above Trend Line
52 weeks +6.2%
Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attention
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Odyssey Therapeutics Stock Is Back In Focus Odyssey Therapeutics (ODTX) is drawing attention after reporting second quarter 2026 results that showed a larger …
EVT
mentioned
Sharemaestro market context
Price below Trend Line
52 weeks -45.5% · Next-week setup negative 44.8%
Zoetis (ZTS) Looked Like a Winner. What Went Wrong?
Brown Advisory, an investment management company, released its "Brown Advisory Global Leaders Strategy" for the second quarter of 2026 investor letter. A copy of the letter can be downloaded here. Brown Advisory's Global Leaders Strategy delivered a net return of 4.6% in the second …
ZOE
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.9%
US Stock Market Today: S&P 500 Futures Climb On Softer Jobs Data And Yields
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. The Morning Bull - US Market Morning Update Monday, Aug, 10 2026 US stock futures are pointing higher this morning, with the S&P …
ZOE
mentioned
Sharemaestro market context
Price below Trend Line
52 weeks -49.9%
ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance
ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance Animal health company Zoetis (NYSE:ZTS) fell short of the market's revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The company's full-year revenue guidance of $9.22 billion at …
ZOE
mentioned
Sharemaestro market context
Price below Trend Line
52 weeks -49.9%
Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program
In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net profitability, raised its 2026 earnings guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurchase program covering 8.7% of shares, and affirmed a US$0.12 quarterly dividend. …
VIA
main company
Sharemaestro market context
Trend signal active
52 weeks +66.1%
Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Viatris stock has delivered a strong 76.1% return over the past year, and the broader valuation checks still indicate the shares may be …
VIA
main company
Sharemaestro market context
Trend signal active
52 weeks +66.1%
Zoetis Q2 Earnings Call Highlights
Key Points Interested in Zoetis Inc.? Here are five stocks we like better. Zoetis reported mixed second-quarter results: Revenue was $2.5 billion, flat reported and down 1% organically, while adjusted EPS rose 4% to $1.87 due partly to share repurchases. Weak U.S. companion-animal demand …
ZOE
main company
Sharemaestro market context
Price below Trend Line
52 weeks -49.9%
Viatris (VTRS) Raises 2026 Guidance, Is The 11% Gap Below Fair Value Enough?
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Viatris raises 2026 guidance alongside completed buyback and fresh product approval Viatris (VTRS) has given investors a busy early August, pairing raised 2026 revenue guidance …
VIA
main company
Sharemaestro market context
Trend signal active
52 weeks +66.1%
Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus
Wall Street’s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P …
Sharemaestro market context Price below Trend Line 52 weeks -49.9%Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The latest research on Viatris centers on a revised price target of US$22 per share and what that figure implies for investors following …
VIA
main company
Sharemaestro market context
Trend signal active
52 weeks +66.1%
Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week
Major healthcare heavyweights, including Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), reported their quarterly earnings this week, pushing the healthcare sector into positive territory after five consecutive sessions of losses. The State Street Health Care Select Sector SPDR ETF [https://seekingalpha.com/symbol/XLV] …
ZOE
mentioned
Sharemaestro market context
Price below Trend Line
52 weeks -49.9%
Elanco Animal Health Q2 Earnings Call Highlights
Key Points Interested in Elanco Animal Health Incorporated? Here are five stocks we like better. Strong Q2 performance: Elanco reported revenue of $1.368 billion, up 10% year over year, while adjusted EBITDA rose 21% to $288 million and adjusted EPS increased 31% to $0.34. …
ZOE
mentioned
Sharemaestro market context
Price below Trend Line
52 weeks -49.9%